结构活性关系探索的imidazo[1,2-a]pyridine系列,以逆转异形选择性和识别强大的SIK1选择性抑制剂
Christophe Peixoto1, Elsa De Lemos1, Laëtitia Cherel1
1Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France.
Bioorganic & medicinal chemistry letters
|September 10, 2025
概括
研究人员开发了第一个选择性抑制盐诱导酶1 (SIK1) 的抑制剂. 化合物27显示出亚纳米级强度和高选择性,使进一步的SIK1研究成为可能.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 盐诱导性酶 (SIK) 是一种调节各种生理过程的氨酸/氨酸蛋白酶.
- SIK抑制是各种疾病的潜在治疗策略,包括恶性瘤和免疫系统疾病.
- 了解SIK1,SIK2和SIK3的异形特异性作用对于向治疗至关重要.
研究的目的:
- 确定和描述SIK1.1的第一个高度选择性抑制剂.
- 开发化学探测器来研究SIK1的特定生物功能.
- 为SIK1选择性建立结构-活动关系.
主要方法:
- 高通量查 (HTS) 以确定最初的SIK抑制剂.
- 结构-活性关系 (SAR) 研究以优化功效和选择性.
- 生物化学和细胞分析以确认开发的化合物的SIK1选择性.
主要成果:
- 一个新的替代模式在一个环上增强了SIK1的功效和选择性.
- 化合物27作为一个亚纳米SIK1抑制剂出现,其选择性超过SIK2和SIK3.3的100倍.
- 化合物27的异形选择性在细胞测定中得到了验证.
结论:
- 首批SIK1选择性抑制剂已成功开发,其中化合物27作为一个关键例子.
- 这些选择性抑制剂为剖析SIK1特异性的生物作用提供了有价值的工具.
- 建议对潜在的目标外活动,特别是对氨酸激酶的潜在活动保持谨慎.
相关概念视频
Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Enzyme Inhibition
91.6K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
91.6K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.8K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.8K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
925
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
925


